Freemelt (FREEM) ABGSC Investor Days summary
Event summary combining transcript, slides, and related documents.
ABGSC Investor Days summary
11 Jan, 2026Company overview and strategy
Founded in 2017 by engineers with deep industry experience, aiming for leadership in metal 3D printing by 2030.
Focuses on complex materials and demanding applications in defense, med tech, and energy, leveraging a modular system.
Transitioning from academic/research customers to industrial clients, with 29 machines sold since 2019.
Board and leadership strengthened with technical and commercial expertise, including industry veterans.
Debt-free, with over SEK 200 million invested in technology and organizational readiness for scaling.
Technology and product differentiation
Uses electron beam powder bed fusion in a vacuum chamber, enabling high-purity production, especially for copper.
Modular system allows preparation and post-processing outside the machine, increasing productivity and reducing costs.
Active cooling system further reduces downtime, enhancing machine availability.
Focuses on copper, tungsten, and titanium, each chosen for unique value in target industries.
Only provider able to produce fully dense, crack-free tungsten parts at required productivity and quality.
Market focus and customer engagement
High demand in defense (notably for tungsten and copper), energy (fusion reactors), and med tech (implants).
Signed contracts with two major implant OEMs; both are experienced in additive manufacturing and are in proof of concept phases.
Over 20 ongoing industrial engagements, up from three in 2023, indicating strong momentum.
U.S. market driven by coordinated programs and qualification through universities/national labs; Europe is more sector-driven.
Aftermarket and recurring revenue expected to grow as industrial adoption increases.
Latest events from Freemelt
- First industrial eMELT sale, OEM order, and machine sales growth amid ongoing losses.FREEM
Q3 20248 Jul 2026 - Q2 saw high activity, new orders, and strategic partnerships despite a wider loss.FREEM
Q2 20248 Jul 2026 - Record sales, fusion breakthroughs, and China entry drive growth in AM and medtech.FREEM
Investor Update1 Jul 2026 - Scaling up with 162% revenue growth, new funding, and global expansion in MedTech, defense, and fusion.FREEM
Investor update2 Jun 2026 - Q1 net sales rose 116% YoY, with strong margins and key sector collaborations advancing.FREEM
Q1 20265 May 2026 - Sales up 172% to SEK 54.5m, installed base up 40%, and strong growth in key sectors.FREEM
Q4 202519 Feb 2026 - Strong Q4 growth, major orders, and capital raise drive expansion in core sectors.FREEM
Q4 202423 Dec 2025 - Record Q2 sales and global expansion drive strong growth and order intake.FREEM
Q2 202523 Nov 2025 - Record order book and SEK 90M rights issue drive growth in defense, energy, and MedTech.FREEM
Q1 202521 Nov 2025